ID   PPMI.I.1025.1
AC   CVCL_D5NI
SY   PPMI3452; PPMI_3452; CDIi051-A; FCDI_11345
DR   BioSamples; SAMEA115473836
DR   hPSCreg; CDIi051-A
DR   Wikidata; Q127383208
RX   PubMed=34434090;
RX   PubMed=36950378;
WW   https://www.ppmi-info.org/access-data-specimens/download-data
WW   https://www.michaeljfox.org/sites/default/files/media/document/2018%20-%20PDTC%20-%20NKP%20Poster%20on%20iPSCs.pdf
CC   Part of: Parkinson's Progression Markers Initiative (PPMI) cell line panel.
CC   Population: Caucasian, not Hispanic.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: PPMI study cohort HC, PPMI study subgroup healthy control.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   71Y
CA   Induced pluripotent stem cell
DT   Created: 02-05-24; Last updated: 10-09-24; Version: 2
//
RX   PubMed=34434090; DOI=10.3389/fnmol.2021.734273; PMCID=PMC8381147;
RA   Nguyen D., Bharat V., Conradson D.M., Nandakishore P., Wang X.-N.;
RT   "Miro1 impairment in a Parkinson's at-risk cohort.";
RL   Front. Mol. Neurosci. 14:734273.1-734273.8(2021).
//
RX   PubMed=36950378; DOI=10.1016/j.xgen.2023.100261; PMCID=PMC10025424;
RA   Bressan E., Reed X., Bansal V., Hutchins E., Cobb M.M., Webb M.G.,
RA   Alsop E., Grenn F.P., Illarionova A., Savytska N., Violich I.,
RA   Broeer S., Fernandes N., Sivakumar R., Beilina A., Billingsley K.J.,
RA   Berghausen J., Pantazis C.B., Pitz V., Patel D., Daida K.,
RA   Meechoovet B., Reiman R., Courtright-Lim A., Logemann A., Antone J.,
RA   Barch M., Kitchen R., Li Y., Dalgard C.L., Rizzu P., Hernandez D.G.,
RA   Hjelm B.E., Nalls M.A., Gibbs J.R., Finkbeiner S., Cookson M.R.,
RA   Van Keuren-Jensen K., Craig D.W., Singleton A.B., Heutink P.,
RA   Blauwendraat C.;
RG   American Genome Center;
RT   "The Foundational Data Initiative for Parkinson Disease: enabling
RT   efficient translation from genetic maps to mechanism.";
RL   Cell Genom. 3:100261.1-100261.25(2023).
//